Home
Market Capitalization of Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd
NSE: AKUMS
Market Cap
Key Highlights
- The Market Cap of Akums Drugs & Pharmaceuticals Ltd is ₹ 7813 crore as of 21 Feb 25 .
- The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 496.45 as of 21 Feb 15:30 .

Akums Drugs & Pharmaceuticals Ltd
NSE: AKUMS
Share Price
Market Price of Akums Drugs & Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 496.45 |
20 Feb 2025 | 511.75 |
19 Feb 2025 | 494.7 |
18 Feb 2025 | 501.8 |
17 Feb 2025 | 516.1 |
14 Feb 2025 | 524.3 |
13 Feb 2025 | 550.15 |
12 Feb 2025 | 549.55 |
11 Feb 2025 | 541.4 |
10 Feb 2025 | 571.25 |
BlinkX Score for Akums Drugs & Pharmaceuticals Ltd
Asset Value vs Market Value of Akums Drugs & Pharmaceuticals Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of Market Cap
Key Valuation Metric of Akums Drugs & Pharmaceuticals Ltd
Historical P/E Ratio of Akums Drugs & Pharmaceuticals Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Akums Drugs & Pharmaceuticals Ltd
Historical Revenue of Akums Drugs & Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Akums Drugs & Pharmaceuticals Ltd
Historical EBITDA of Akums Drugs & Pharmaceuticals Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Akums Drugs & Pharmaceuticals Ltd
Historical Net Profit of Akums Drugs & Pharmaceuticals Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Akums Drugs & Pharmaceuticals Ltd
Dividend Payout Over Time
About Akums Drugs & Pharmaceuticals Ltd
- Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
- They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
- Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
- Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.
Akums Drugs & Pharmaceuticals Ltd News Hub
Akums Drugs and Pharmaceuticals rises on debut
The scrip was listed at Rs 725, exhibiting a 6.77% premium to the issue price. So far, the stock has
Read more
06 Aug 24
Akums Drugs and Pharmaceuticals IPO ends with strong subscription
The initial public offer (IPO) of Akums Drugs and Pharmaceuticals received 96,36,79,134 bids for sha
Read more
02 Aug 24
Akums Drugs and Pharmaceuticals IPO subscribed 63.44 times
The initial public offer (IPO) of Akums Drugs and Pharmaceuticals received 96,18,57,204 bids for sha
Read more
01 Aug 24
Akums Drugs & Pharmaceuticals reports consolidated net profit of Rs 60.17 crore in the June 2024 quarter
Net profit of Akums Drugs & Pharmaceuticals reported to Rs 60.17 crore in the quarter ended June 202
Read more
26 Aug 24